Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000778

Drug Information
Synonyms1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; E 0516; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; Edolan; KBioGR_000680; MLS000028474; Spectrum4_000410; SPECTRUM1501005; CID3308; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; BPBio1_000333; Etodolac, (+-)-Isomer; D00315; Etodolac, Monosodium Salt, (S)-Isomer; Lodine SR; Prestwick1_000231; 41340-25-4; NSC 282126; Etodolac, Monosodium Salt, (+-) Isomer; Osteluc; AC1L1FN2; Etodolic acid; Prestwick_209; SPBio_002222; HMS2092O20; NCGC00015399-04; LS-7393; E0516_SIGMA; SPBio_001374; D017308; CCRIS 3923; DivK1c_000147; HMS500H09; AC-4231; etodolac; Hypen; Spectrum_001244; Prestwick2_000231; Etodolac (JP15/USP/INN); AB00052194; Prestwick0_000231; MLS001077315; BSPBio_000301; NINDS_000147; Etodolac [USAN:INN:BAN]; KBio2_001724; SBB067257; AY24236; KBioSS_001724; 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; Ramodar; NCGC00089769-05; (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; IDI1_000147; Acid, Etodolic; CHEBI:4909; Lodine; CPD000058443; NCGC00089769-04; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; AY 24,236; RAK-591; AY24,236; Etodolacetodolic acid; Lodine XL; AY-24236; AY 24236; Etodolaco; Prestwick3_000231; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-; Etodolacum [INN-Latin]; CHEMBL622; Etodolac [USAN:BAN:INN]; BRD-A74667430-001-05-3; Ultradol; Lodine (TN); Spectrum2_001387; KBio2_004292; Lopac0_000479; Spectrum3_001429; KBio1_000147; Etodolaco [INN-Spanish]; NCGC00089769-07; NCGC00089769-03; MolPort-001-759-084; [1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid; HMS1921B09; NCGC00015399-11; KBio2_006860; KBio3_002358; SMR000058443; DB00749; 110781-63-0 (mono-hydrochloride salt); SAM002589968; AY-24,236; Etodolacum; NCGC00089769-06; NSC282126; Etodolac, Monosodium Salt; NCGC00089769-02; 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid; Spectrum5_001347; HMS1568P03; CHEBI:126431; EU-0100479; UNII-2M36281008; Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; BSPBio_003138    
Trade NameLodine SR; Eccoxolac    
CompanyMeda Pharmaceuticals    
IndicationPainApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnalgesics    
CAS NumberCAS 41340-25-4
PubChem Compound IDCID 3308.    
PubChem Substance IDSID 143623.    
SuperDrug ATC IDM01AB08;    
SuperDrug CAS ID041340254;    
TargetProstaglandin G/H synthase 2Inhibitor[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074819 To Reference
Ref 2Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. Epub 2007 Jul 2. To Reference
Ref 3Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001 Jul;8(7):S35-9. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543